DECITABINA ACCORD 50mg powder for concentrate infusion solution medication leaflet

L01BC08 • decitabine • Antineoplastic and immunomodulating agents | Antimetabolites | Pyrimidine analogues

Decitabine is a hypomethylating agent used for the treatment of myelodysplastic syndromes and acute myeloid leukemia. It works by inhibiting DNA methyltransferase, leading to the reactivation of tumor suppressor genes and inhibition of cancer cell growth.

The medication is administered via intravenous infusion, usually in treatment cycles, with the dose adjusted based on the patient's condition and response to therapy. Common side effects include nausea, anemia, neutropenia, and thrombocytopenia.

Decitabine is contraindicated in patients with hypersensitivity to the active substance or any of its excipients. Its use also requires careful monitoring to prevent severe hematological complications.

This medication is an important option for patients with malignant hematological disorders, helping to improve their prognosis.